查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球临床试验用品市场：市场规模、市场份额、趋势分析、机遇和预测：按产品、临床阶段、治疗用途、最终用途、地区划分 (2019-2029)
市场调查报告书
商品编码
1217686

全球临床试验用品市场：市场规模、市场份额、趋势分析、机遇和预测：按产品、临床阶段、治疗用途、最终用途、地区划分 (2019-2029)

Clinical Trial Supplies Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Product ; By Clinical Phase ; By Therapeutic Use ; By End Use ; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 270 Pages | 商品交期: 2-3个工作天内

价格
简介目录

全球临床试验用品市场规模将从2022年的20亿美元增长到2029年的29亿美元，在2023年至2029年的预测期内（2022-2028）占5.09%，预计复合年增长率为 各种慢性病和流行病的流行率上升，製药公司、政府和研究机构对临床试验的大量投资正在推动市场的增长。

本报告考察了全球临床试验用品市场，并提供了全面的信息，包括市场概况、市场分析和公司概况。

内容

第一章研究框架

第 2 章执行摘要

第 3 章全球临床试验用品市场洞察

  • 行业价值链分析
    • DROC 分析
    • 司机
      • 药物和生物製药的研发费用增加
      • 慢性病和传染病的负担不断增加
    • 约束因素
      • 药物不良反应
    • 机会
      • 新兴国家新药开发试验的出现
    • 任务
      • COVID-19 对供应链的影响
  • 技术进步/最新发展
  • 监管框架
  • 波特的五力分析
    • 供应商的议价能力
    • 买家的议价能力
    • 新进入者的威胁
    • 替代品的威胁
    • 竞争激烈程度

第 4 章全球临床试验用品市场概述

  • 市场规模和预测（2019-2029 年）
    • 按金额（百万美元）
  • 市场份额和预测
    • 按产品分类
      • 製造业
      • 供应链管理
      • 物流
      • 存储和分发
      • 其他
    • 按临床分期
      • 第一阶段
      • 第二阶段
      • 第三阶段
      • 其他
    • 通过治疗用途
      • 肿瘤
      • 中枢神经系统
      • 心血管
      • 感染
      • 代谢紊乱
      • 其他
    • 按最终用途
      • 医药
      • 生物製剂
      • 医疗设备
      • 其他
    • 按地区
      • 北美
      • 欧洲
      • 亚太地区
      • 拉丁美洲
      • 中东和非洲

第五章北美临床试验用品市场

第 6 章欧洲临床试验用品市场

第七章亚太临床试验用品市场

第 8 章拉丁美洲临床试验用品市场

第9章中东和非洲临床试验用品市场

第10章竞争格局

  • 主要公司及其产品列表
  • 全球临床试验供应公司的市场份额分析（2022 年）
  • 竞争基准：按操作参数
  • 重大战略发展（合併、收购、合作等）

第 11 章 COVID-19 对全球临床试验用品市场的影响

第12章公司概况（公司概况、财务矩阵、竞争格局、关键人才、主要竞争对手、联繫人、战略展望、SWOT分析）

  • Alamc Group
  • Catalent, Inc.
  • PCI Services
  • Parexel International Corporation
  • Sharp Packaging Services
  • Biocair
  • O&M Movianto
  • KLIFO A/S
  • Thermo Fisher Scientific, Inc.
  • Movianto
  • Sharp
  • Catalent, Inc
  • Bionical Ltd.
  • Alium Medical Limited
  • 其他

第 13 章关键战略建议

第 14 章研究方法论

简介目录
Product Code: BWC20102

Global Clinical Trial Supplies Market Size Booming to Touch USD 3 Billion by 2029

Global clinical trial supplies market is gaining traction because of an increasing focus on R&D innovative medicines to treat growing prevalence of various chronic and communicable illnesses as well as significant investments in clinical trials by pharmaceutical firms, governments, and research institutions.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global clinical trial supplies market size at USD 2 billion in 2022. During the forecast period between 2023 and 2029, the global clinical trial supplies market size is projected to grow at a steady CAGR of 5.09% reaching a value of USD 2.9 billion by 2029. The increased prevalence of different chronic and communicable illnesses as well as significant investments in clinical trials by pharmaceutical firms, governments, and research institutions are key growth drivers for the global clinical trial supplies market. The global clinical trial supplies market is expected to grow during the forecast period as a result of the pharmaceutical and biotechnology firms' increasing investments in research and development activities for medication development.

Global Clinical Trial Supplies Market - Overview:

Clinical trials are research projects conducted on human subjects to assess a therapeutic, surgical, or behavioral intervention. Clinical trials often fall into one of three categories: Interventional studies seek to learn more about a specific intervention or kind of treatment. Observational studies seek to understand how individuals behave in various contexts. Feasibility studies are intended to determine whether the primary research can be conducted. The provision of materials needed to execute a clinical trial is known as clinical supply or clinical trial supply. This includes the 24-hour collection and distribution of biological specimens (including infectious samples), experimental medications, kits, and other research materials and supplies, as well as knowledge and help.

Global Clinical Trial Supplies Market - By End Use:

Based on end use, the global clinical trial supplies market is segmented into pharmaceuticals, biologics, medical devices, and others. Pharmaceutical companies account for the highest market share owing to the increasing number of clinical trials for drug development. Pharmaceutical companies use clinical trial supplies for collection and delivery of biological specimens, investigational drugs, and others. However, the biologics segment is expected to gain high traction during the forecast period owing to extensive research activities around the development of drugs from biologics such as blood, proteins, viruses, or living organisms.

Impact of COVID-19 on the Global Clinical Trial Supplies Market

COVID-19 elevated the critical nature of clinical trial supplies and their importance to the healthcare market. Although the global clinical trial supplies market was initially hindered during the pandemic period as the imposition of lockdowns in various countries halted the clinical trials of various therapeutic purposes, which significantly impacted the market growth. To complete vaccine development activities after the pandemic outbreak and stop any further human deaths, clinical trial sponsors, their clinical research organizations, study teams, and other important stakeholders, such as vendors, had to work cooperatively to secure clinical trial supplies.

Competitive Landscape:

Major players operating in the global Clinical Trial Supplies market include Almac Group, Catalent, Inc., PCI Services, Parexel International Corporation, Sharp Packaging Services, Biocair, O&M Movianto, KLIFO A/S, Thermo Fisher Scientific, Inc., Movianto, Sharp, Catalent, Inc, Bionical Ltd., and Alium Medical Limited. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and the Global Clinical Trial Supplies Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Clinical Trial Supplies Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Clinical Trial Supplies Market Insights

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. DROC Analysis
    • 3.1.2. Growth Drivers
      • 3.1.2.1. Increasing Pharmaceutical and Biopharmaceutical R&D Expenditures
      • 3.1.2.2. Rising Burden of Chronic and Communicable Diseases
    • 3.1.3. Restraints
      • 3.1.3.1. Adverse Drug Reactions
    • 3.1.4. Opportunities
      • 3.1.4.1. Rising New Drug Development Trial in Emerging Countries
    • 3.1.5. Challenges
      • 3.1.5.1. Impact of COVID-19 on Supply Chain
  • 3.2. Technology Advancements/Recent Developments
  • 3.3. Regulatory Framework
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of New Entrants
    • 3.4.4. Threat of Substitutes
    • 3.4.5. Intensity of Rivalry

4. Global Clinical Trial Supplies Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Million)
  • 4.2. Market Share & Forecast
    • 4.2.1. By Product
      • 4.2.1.1. Manufacturing
      • 4.2.1.2. Supply Chain Management
      • 4.2.1.3. Logistics
      • 4.2.1.4. Storage & Distribution
      • 4.2.1.5. Others
    • 4.2.2. By Clinical Phase
      • 4.2.2.1. Phase I
      • 4.2.2.2. Phase II
      • 4.2.2.3. Phase III
      • 4.2.2.4. Others
    • 4.2.3. By Therapeutic use
      • 4.2.3.1. Oncology
      • 4.2.3.2. CNS
      • 4.2.3.3. Cardiovascular
      • 4.2.3.4. Infectious Disease
      • 4.2.3.5. Metabolic Disorders
      • 4.2.3.6. Others
    • 4.2.4. By End Use
      • 4.2.4.1. Pharmaceutical
      • 4.2.4.2. Biologics
      • 4.2.4.3. Medical Device
      • 4.2.4.4. Others
    • 4.2.5. By Region
      • 4.2.5.1. North America
      • 4.2.5.2. Europe
      • 4.2.5.3. Asia Pacific (APAC)
      • 4.2.5.4. Latin America
      • 4.2.5.5. Middle East and Africa (MEA)

5. North America Clinical Trial Supplies Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product
    • 5.2.2. By Clinical Phase
    • 5.2.3. By Therapeutic use
    • 5.2.4. By End Use
    • 5.2.5. By Country
      • 5.2.5.1. US
      • 5.2.5.1.1. By Product
      • 5.2.5.1.2. By Clinical Phase
      • 5.2.5.1.3. By Therapeutic use
      • 5.2.5.1.4. By End Use
      • 5.2.5.2. Canada
      • 5.2.5.2.1. By Product
      • 5.2.5.2.2. By Clinical Phase
      • 5.2.5.2.3. By Therapeutic use
      • 5.2.5.2.4. By End Use

6. Europe Clinical Trial Supplies Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Clinical Phase
    • 6.2.3. By Therapeutic use
    • 6.2.4. By End Use
    • 6.2.5. By Country
      • 6.2.5.1. Germany
      • 6.2.5.1.1. By Product
      • 6.2.5.1.2. By Clinical Phase
      • 6.2.5.1.3. By Therapeutic use
      • 6.2.5.1.4. By End Use
      • 6.2.5.2. UK
      • 6.2.5.2.1. By Product
      • 6.2.5.2.2. By Clinical Phase
      • 6.2.5.2.3. By Therapeutic use
      • 6.2.5.2.4. By End Use
      • 6.2.5.3. Italy
      • 6.2.5.3.1. By Product
      • 6.2.5.3.2. By Clinical Phase
      • 6.2.5.3.3. By Therapeutic use
      • 6.2.5.3.4. By End Use
      • 6.2.5.4. France
      • 6.2.5.4.1. By Product
      • 6.2.5.4.2. By Clinical Phase
      • 6.2.5.4.3. By Therapeutic use
      • 6.2.5.4.4. By End Use
      • 6.2.5.5. Spain
      • 6.2.5.5.1. By Product
      • 6.2.5.5.2. By Clinical Phase
      • 6.2.5.5.3. By Therapeutic use
      • 6.2.5.5.4. By End Use
      • 6.2.5.6. The Netherlands
      • 6.2.5.6.1. By Product
      • 6.2.5.6.2. By Clinical Phase
      • 6.2.5.6.3. By Therapeutic use
      • 6.2.5.6.4. By End Use
      • 6.2.5.7. Rest of Europe
      • 6.2.5.7.1. By Product
      • 6.2.5.7.2. By Clinical Phase
      • 6.2.5.7.3. By Therapeutic use
      • 6.2.5.7.4. By End Use

7. Asia-Pacific Clinical Trial Supplies Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Clinical Phase
    • 7.2.3. By Therapeutic use
    • 7.2.4. By End Use
    • 7.2.5. By Country
      • 7.2.5.1. China
      • 7.2.5.1.1. By Product
      • 7.2.5.1.2. By Clinical Phase
      • 7.2.5.1.3. By Therapeutic use
      • 7.2.5.1.4. By End Use
      • 7.2.5.2. India
      • 7.2.5.2.1. By Product
      • 7.2.5.2.2. By Clinical Phase
      • 7.2.5.2.3. By Therapeutic use
      • 7.2.5.2.4. By End Use
      • 7.2.5.3. Japan
      • 7.2.5.3.1. By Product
      • 7.2.5.3.2. By Clinical Phase
      • 7.2.5.3.3. By Therapeutic use
      • 7.2.5.3.4. By End Use
      • 7.2.5.4. South Korea
      • 7.2.5.4.1. By Product
      • 7.2.5.4.2. By Clinical Phase
      • 7.2.5.4.3. By Therapeutic use
      • 7.2.5.4.4. By End Use
      • 7.2.5.5. Australia & New Zealand
      • 7.2.5.5.1. By Product
      • 7.2.5.5.2. By Clinical Phase
      • 7.2.5.5.3. By Therapeutic use
      • 7.2.5.5.4. By End Use
      • 7.2.5.6. Indonesia
      • 7.2.5.6.1. By Product
      • 7.2.5.6.2. By Clinical Phase
      • 7.2.5.6.3. By Therapeutic use
      • 7.2.5.6.4. By End Use
      • 7.2.5.7. Malaysia
      • 7.2.5.7.1. By Product
      • 7.2.5.7.2. By Clinical Phase
      • 7.2.5.7.3. By Therapeutic use
      • 7.2.5.7.4. By End Use
      • 7.2.5.8. Singapore
      • 7.2.5.8.1. By Product
      • 7.2.5.8.2. By Clinical Phase
      • 7.2.5.8.3. By Therapeutic use
      • 7.2.5.8.4. By End Use
      • 7.2.5.9. Philippines
      • 7.2.5.9.1. By Product
      • 7.2.5.9.2. By Clinical Phase
      • 7.2.5.9.3. By Therapeutic use
      • 7.2.5.9.4. By End Use
      • 7.2.5.10. Vietnam
      • 7.2.5.10.1. By Product
      • 7.2.5.10.2. By Clinical Phase
      • 7.2.5.10.3. By Therapeutic use
      • 7.2.5.10.4. By End Use
      • 7.2.5.11. Rest of APAC
      • 7.2.5.11.1. By Product
      • 7.2.5.11.2. By Clinical Phase
      • 7.2.5.11.3. By Therapeutic use
      • 7.2.5.11.4. By End Use

8. Latin America Clinical Trial Supplies Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Clinical Phase
    • 8.2.3. By Therapeutic use
    • 8.2.4. By End Use
    • 8.2.5. By Country
      • 8.2.5.1. Brazil
      • 8.2.5.1.1. By Product
      • 8.2.5.1.2. By Clinical Phase
      • 8.2.5.1.3. By Therapeutic use
      • 8.2.5.1.4. By End Use
      • 8.2.5.2. Mexico
      • 8.2.5.2.1. By Product
      • 8.2.5.2.2. By Clinical Phase
      • 8.2.5.2.3. By Therapeutic use
      • 8.2.5.2.4. By End Use
      • 8.2.5.3. Argentina
      • 8.2.5.3.1. By Product
      • 8.2.5.3.2. By Clinical Phase
      • 8.2.5.3.3. By Therapeutic use
      • 8.2.5.3.4. By End Use
      • 8.2.5.4. Peru
      • 8.2.5.4.1. By Product
      • 8.2.5.4.2. By Clinical Phase
      • 8.2.5.4.3. By Therapeutic use
      • 8.2.5.4.4. By End Use
      • 8.2.5.5. Rest of LATAM
      • 8.2.5.5.1. By Product
      • 8.2.5.5.2. By Clinical Phase
      • 8.2.5.5.3. By Therapeutic use
      • 8.2.5.5.4. By End Use

9. Middle East & Africa Clinical Trial Supplies Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Clinical Phase
    • 9.2.3. By Therapeutic use
    • 9.2.4. By End Use
    • 9.2.5. By Country
      • 9.2.5.1. Saudi Arabia
      • 9.2.5.1.1. By Product
      • 9.2.5.1.2. By Clinical Phase
      • 9.2.5.1.3. By Therapeutic use
      • 9.2.5.1.4. By End Use
      • 9.2.5.2. UAE
      • 9.2.5.2.1. By Product
      • 9.2.5.2.2. By Clinical Phase
      • 9.2.5.2.3. By Therapeutic use
      • 9.2.5.2.4. By End Use
      • 9.2.5.3. Qatar
      • 9.2.5.3.1. By Product
      • 9.2.5.3.2. By Clinical Phase
      • 9.2.5.3.3. By Therapeutic use
      • 9.2.5.3.4. By End Use
      • 9.2.5.4. Kuwait
      • 9.2.5.4.1. By Product
      • 9.2.5.4.2. By Clinical Phase
      • 9.2.5.4.3. By Therapeutic use
      • 9.2.5.4.4. By End Use
      • 9.2.5.5. South Africa
      • 9.2.5.5.1. By Product
      • 9.2.5.5.2. By Clinical Phase
      • 9.2.5.5.3. By Therapeutic use
      • 9.2.5.5.4. By End Use
      • 9.2.5.6. Nigeria
      • 9.2.5.6.1. By Product
      • 9.2.5.6.2. By Clinical Phase
      • 9.2.5.6.3. By Therapeutic use
      • 9.2.5.6.4. By End Use
      • 9.2.5.7. Algeria
      • 9.2.5.7.1. By Product
      • 9.2.5.7.2. By Clinical Phase
      • 9.2.5.7.3. By Therapeutic use
      • 9.2.5.7.4. By End Use
      • 9.2.5.8. Rest of MEA
      • 9.2.5.8.1. By Product
      • 9.2.5.8.2. By Clinical Phase
      • 9.2.5.8.3. By Therapeutic use
      • 9.2.5.8.4. By End Use

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Clinical Trial Supplies Company Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Clinical Trial Supplies Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 12.1. Alamc Group
  • 12.2. Catalent, Inc.
  • 12.3. PCI Services
  • 12.4. Parexel International Corporation
  • 12.5. Sharp Packaging Services
  • 12.6. Biocair
  • 12.7. O&M Movianto
  • 12.8. KLIFO A/S
  • 12.9. Thermo Fisher Scientific, Inc.
  • 12.10. Movianto
  • 12.11. Sharp
  • 12.12. Catalent, Inc
  • 12.13. Bionical Ltd.
  • 12.14. Alium Medical Limited
  • 12.15. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations